Recursion's stock has been consistently rated as "Hold" by this analyst due to skepticism about its AI-driven drug discovery approach and its financial instability. The company's IPO raised over $500 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback